Alvotech Completes Key FDA Inspection to Keep US Expansion Plans on Schedule

2026-05-11 companies

Reykjavik, Monday, 11 May 2026.
Following a critical FDA inspection in Iceland, Alvotech remains on track for its second-quarter US product submissions, prioritizing long-term market growth despite a recent 20% quarterly revenue dip.

Navigating Regulatory Hurdles for U.S. Expansion

On May 11, 2026, global biopharmaceutical company Alvotech (NASDAQ: ALVO) announced the completion of a routine Current Good Manufacturing Practice (cGMP) surveillance inspection by the U.S. Food and Drug Administration (FDA) at its Reykjavik, Iceland facility [1]. The inspection, which commenced on April 29, 2026, concluded with the FDA issuing a Form 483 on May 8, 2026 [1][2]. Despite the observations noted in the form, Alvotech’s management expressed confidence that the issues can be swiftly resolved without raising substantial concerns [1]. This regulatory milestone is critical, as it clears the path for the company to proceed with planned Biologics License Application (BLA) resubmissions in the second quarter of 2026 [1][2].

Short-Term Financial Sacrifices for Long-Term Gains

Alvotech’s recent financial performance reflects the deliberate operational slowdowns implemented to accommodate these facility improvements and regulatory remediations. During the company’s first-quarter 2026 earnings call on May 7, 2026, Alvotech reported total revenues of $106 million, representing a 20% year-over-year decline [2][3]. This reduction was primarily driven by a temporary manufacturing slowdown related to an FDA remediation plan following Complete Response Letters (CRLs) received in 2025 [5]. Consequently, the product margin fell to 11% for the quarter [2][4].

Strategic Partnerships and Expanding Capacity

To bolster its future supply chain and mitigate manufacturing bottlenecks, Alvotech announced a strategic manufacturing agreement with Fujifilm Biotechnologies on May 5, 2026 [2][5]. This partnership is designed to supply multiple products specifically for the U.S. market, with sellable batches expected to be available in the second half of 2027 [2][5]. This move aligns with management’s characterization of 2027 as a “step-change year” for the company, driven by expanded product portfolios and increased manufacturing output following the completion of facility enhancements [4][5].

Aggressive Targets for Late 2026 and Beyond

Looking ahead, Alvotech has set ambitious financial targets for the remainder of the year. The company is guiding for full-year 2026 revenues between $650 million and $700 million, alongside adjusted EBITDA projections ranging from $180 million to $220 million [2][4]. Achieving these targets will require a significant acceleration in the latter half of the year, heavily dependent on the successful resumption of normal production operations, which management expects to occur in the second quarter of 2026 [5].

Sources

Alvotech FDA inspection